Blocklisting Six Monthly Return

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.HUTCHMED (China) Limited 和黄医药（中国）有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 13) OVERSEAS REGULATORY ANNOUNCEMENT This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on June 28 2024.By Order of the Board Edith Shih Non-executive Director and Company Secretary Hong Kong June 28 2024 As at the date of this announcement the Directors of the Company are: Chairman and Non-executive Director: Non-executive Directors: Dr Dan ELDAR Ms Edith SHIH Ms Ling YANG Executive Directors: Dr Weiguo SU Independent Non-executive Directors: (Chief Executive Officer and Mr Paul Rutherford CARTER Chief Scientific Officer) (Senior Independent Director) Mr CHENG Chig Fung Johnny Dr Renu BHATIA (Chief Financial Officer) Mr Graeme Allan JACK Professor MOK Shu Kam TonyBlocklisting Six Monthly Return Hong Kong Shanghai & Florham Park NJ — Friday June 28 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”) 3. Period of return: From December 29 2023 to June 28 2024 4. Balance under scheme from 2015 HUTCHMED Share Option Scheme: 46847218 ordinary previous return: shares of US$0.1 each 5. The amount by which the block 2015 HUTCHMED Share Option Scheme: Nil scheme has been increased if the scheme has been increased since the date of the last return: 6. Number of securities 2015 HUTCHMED Share Option Scheme: 103450 issued/allotted under scheme during period: 7. Balance under scheme not yet 2015 HUTCHMED Share Option Scheme: 46743768 ordinary issued/allotted at end of the shares of US$0.1 each period: 8. Number and class of securities 25198880 ordinary shares of US$0.1 each admitted on June 17 originally listed and the date of 2019 (to replace the Company’s previous block admission admission: schemes following the Company’s share subdivision which took effect on May 30 2019) 9. Total number of securities in 871359720 ordinary shares of US$0.1 each issue at the end of the period: Name of contact: Weiguo Su Address of contact: Level 18 The Metropolis Tower 10 Metropolis Drive Hung Hom Kowloon Hong Kong Telephone number of contact: +852 2121 8200 About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative commercial-stage biopharmaceutical company.It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5000 personnel across all its companies at the center of which is a team of about 1800 in oncology/immunology.Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world with its first three oncology drugs marketed in China the first of which is also marketed in the U.S.For more information please visit: www.hutch-med.com or follow us on LinkedIn.CONTACTS Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries Ben Atwell / Alex Shaw FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com Zhou Yi Brunswick +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Nominated Advisor Atholl Tweedie / Freddy Crossley / +44 (20) 7886 2500 Rupert Dearden Panmure Gordon